The University of Strathclyde in Glasgow is home to around 25,000 students and 4,000 staff, placing useful learning and real-world impact at the heart of its activities.
The funding round was backed by a group of existing investors alongside a grant from the European Innovation Council.
"This is a very significant funding milestone in our mission to detect cancer early and improve survival and quality of life for patients. Having demonstrated our multi-cancer capability, we can now focus on building the pipeline of organ-specific tests, beginning with a multi-center study to gain regulatory approval for the brain cancer test. We will also expand our data on colorectal cancer, one of the leading causes of death worldwide, and continue our work on collaborative projects."
The pre seed round was co led by Techstart Ventures and Nauta Capital to support team expansion and platform development.
"We are thrilled with the opportunities this investment creates to develop Lupovis’ dynamic deception capabilities. Our system uses artificial intelligence to create scenarios which mirror the existing infrastructure of an organisation and engages the attacker into believing they are progressing towards assets of value, turning networks from a flock of sheep to a pack of wolves. We are in a unique position where we have unrivalled data on attacker techniques, methods and behaviour. We will feed this data into our platform, so our customers will always remain one step ahead of attackers, predicting their next move, long before they actually make it."
The Glasgow space technology start-up has raised £3.1m from investors including Space Capital and the Scottish National Investment Bank to scale its connectivity platform.
"We immediately saw the opportunity with R3-IoT, which is essentially Nest for organisations with remote industrial facilities. This is the right company at the right time that will benefit tremendously from new backhaul capacity coming online through low-Earth orbit satellite communications."
Norcliffe Capital led the latest investment as the cancer diagnostics firm reached its £3.5m target.
"Achieving the £3.5m target enables us to accelerate our plans. We will shortly complete our move into new lab and office facilities and increase staffing to 15, bringing forward key operational and commercial appointments."
